Olaplex went public in 2021 at a valuation above $13 billion. In 2026 it sold for $1.4 billion, a drop of roughly 90 percent, according to deal tracking from TNGE. In the same stretch, Oura Ring closed a Series E at $10.9 billion, more than double its $5 billion valuation from December 2024, per The Fashion Law's health and wellness M&A tracker. Same industry. Same five years. Opposite outcomes. If you are holding equity, options, or a job title in wellness, the question is not whether the sector is growing. It is which side of that split you are on.
The headline number says growth. The global wellness economy reached $4.8 trillion in 2026, up from $3.7 trillion in 2020, according to the Global Wellness Institute. That is real. It is also the wrong number to build a career or a portfolio around, because it averages a market that no longer behaves like one market. Below the aggregate, there are two distinct businesses wearing the same industry badge: durable, evidence-backed infrastructure, and trend-dependent consumer brands that got priced like software companies during a period when capital had nowhere else profitable to go.
The winners: data, defensibility, distribution
What connects the companies that held or grew their valuations is not category. Wearables, supplements, and mental health apps all have winners. What they share is a defensible mechanism: either proprietary data, a subscription habit, or clinical validation that a competitor cannot copy in a weekend.
Oura's jump to $10.9 billion rests on a data moat, years of sleep and readiness metrics from millions of rings that get better with scale and are hard for a new entrant to replicate quickly, per the same Fashion Law tracker. Calm, the meditation app, was valued at $2 billion as of January 2025, and its economics explain why: premium subscriptions at $69.99 a year or $399.99 for lifetime access, a pricing ladder built for retention, not one-time purchase, according to CNBC's reporting on the round. AG1, the greens powder brand, cleared $1 billion in valuation on estimated annual revenue of $300 to $500 million, a multiple that only works if the subscribe-and-save cohort keeps reordering, per Healthy Guru's 2026 wellness brand valuation review.
The private equity buyers moving into the space now are not chasing growth stories. Thorne, the supplement company, went public in 2021 and was taken private by L Catterton in 2026 for $680 million, at a point where its annual revenue had surpassed $500 million in 2025, according to Glossy's coverage of the wellness M&A cycle. That is a buyer paying roughly 1.4 times revenue for a company with clinical credibility and real sales, not a bet on future growth. Refresco's approximately $790 million acquisition of SunOpta in February 2026 follows the same logic: an established plant-based beverage operator with existing distribution, not a startup with a deck, per the Columbia West Capital Q1 2026 M&A report.
The losers: hype without a mechanism
Olaplex's collapse is not really a story about a bad product. It is a story about what happens when a viral hair-repair brand gets priced as if virality is a moat. It is not. Once the ingredient story stopped being novel and competitors copied the formula, the multiple had nowhere to go but down, and it went down 90 percent, per TNGE's deal data.
The strongest version of the skeptic's case goes further than one brand. Pat McGrath Labs was valued at $1 billion in 2018, and investor stakes have since been marked down 88 percent. Morphe filed for Chapter 11 with $868 million in debt. Drunk Elephant, acquired for $845 million in 2019, is now rumored as a divestiture target after its parent company took impairment charges, alongside Too Faced and Dr. Jart. Analysts covering the deal flow describe the middle market, companies doing $30 to $70 million in revenue without exceptional margins, as the hardest part of the market to transact in right now. That is not a footnote. That is a description of where most wellness brands actually sit: too big to be a scrappy acquisition target, too small to have the data moat or clinical backing that justifies a premium multiple.
This case is correct as far as it goes. The mistake is treating it as evidence that wellness overall is fragile, when it is really evidence that a specific business model, the trend-driven consumer brand with no repeat mechanism and no clinical differentiation, is fragile. Median EV/Revenue multiples for wellness and health companies sat at 1.1x in Q1 2026, only slightly under pre-pandemic levels after correcting from the pandemic peak, according to Finerva's valuation multiples report. That is a normal market pricing normal businesses normally. It is not a market in decline. It is a market that stopped paying growth-stage multiples for consumer packaged goods with no moat, which is a correction, not a collapse.
Where the deal flow is actually going
The volume numbers still look aggressive if you only read the top line. Digital health funding hit $7.1 billion across 216 deals in Q1 2026 alone, with 46 M&A transactions in the same quarter, most with undisclosed valuations, per Galen Growth's Q1 2026 tracking. The undisclosed part matters. Acquirers are not advertising multiples the way they did in 2021, because the multiples are not the story anymore, the fit is. Corporate wellness, the least glamorous corner of the industry, is growing at a plodding 3.1 percent CAGR, from $55.1 billion in 2025 to a projected $70.1 billion by 2033, according to Grand View Research. That is not a trend cycle. That is a procurement line item that HR departments budget for every year regardless of what is happening on TikTok, which is exactly why it will still exist in 2033 while several current wellness brands will not.
The table that should replace the pitch deck
Strip out the marketing language and the pattern is a spreadsheet problem.
| Company | Peak or entry valuation | Outcome | Mechanism |
|---|---|---|---|
| Oura Ring | $5B (Dec 2024) | $10.9B Series E, 2026 | Proprietary biometric data |
| Calm | N/A | $2B, Jan 2025 | Subscription retention |
| AG1 | N/A | $1B+, $300–500M revenue | Subscribe-and-save reorder |
| Thorne | 2021 IPO | $680M take-private, 2026 | Clinical credibility, $500M+ revenue |
| Olaplex | $13B+ IPO, 2021 | $1.4B sale, 2026 (down ~90%) | None once formula was copied |
Every company on the left had a mechanism a competitor could not replicate in a fiscal quarter. Olaplex did not.
Who this analysis serves, and who it does not
If you sell advice, capital, or a career pivot into wellness, the incentive is to describe the entire $4.8 trillion figure as opportunity. It is not, uniformly. Recruiters placing candidates into wellness startups benefit from the growth headline. Investors who already hold positions in mid-market consumer brands benefit from downplaying the middle-market squeeze. The honest read is narrower: the data-moat and clinical-validation businesses are getting paid, the trend-brand middle market is where capital goes to get stuck, at exactly the $30 to $70 million revenue band that analysts flag as the hardest to transact.
This framework fails under a few conditions. If you are building or investing in a category still young enough that no data moat exists yet, in that window growth-at-any-cost can still be rational, because someone will eventually build the moat and being early has value. It also fails if you are optimizing for acquisition by a strategic buyer who wants brand and distribution more than defensibility, the SunOpta and Drunk Elephant playbook, in which case scale and shelf space substitute for a moat. And it fails for anyone with a five-to-ten-year horizon rather than a two-to-three-year one, since categories that look undifferentiated today can consolidate into a durable position later.
None of that changes the near-term decision facing anyone with equity, a job offer, or a fund allocation in this space right now. Ask what happens to the valuation if a competitor copies the product in six months. If the answer is nothing, because the moat is data, clinical evidence, or a subscription habit that took years to build, you are on the Oura side of the ledger. If the answer is the multiple collapses, you already know what happened to Olaplex.